irlabs2023-05-02T11:42:57+00:00Adastra Holdings Reports FY2022 Results; Demonstrating A Second Year of Record Revenueirlabs2023-05-02T11:42:57+00:00May 2, 2023|
irlabs2023-03-16T11:31:15+00:00Adastra Accelerates Growth; 152% Increase in Shipment Volumeirlabs2023-03-16T11:31:15+00:00March 16, 2023|
irlabs2023-03-15T20:38:27+00:00Adastra to Defend Lawsuitirlabs2023-03-15T20:38:27+00:00March 15, 2023|
irlabs2023-03-03T22:03:06+00:00Adastra Labs Clarifies and Retracts Certain Disclosure Related to its Receipt of Health Canada Approval for the Amendment to Include Cocaine Under its Controlled Substances Licenceirlabs2023-03-03T22:03:06+00:00March 3, 2023|
irlabs2023-02-22T21:21:09+00:00Adastra Labs Receives Health Canada Approval for the Amendment to Include Cocaine Under its Controlled Substances Dealer’s Licenseirlabs2023-02-22T21:21:09+00:00February 22, 2023|
irlabs2023-02-14T12:32:34+00:00Leadership Update: Adastra Appoints Lachlan McLeod as CFOirlabs2023-02-14T12:32:34+00:00February 14, 2023|
irlabs2023-02-09T12:37:44+00:00Adastra Completes Transaction to Terminate Legacy Supply Agreement, Bringing Phyto Extractions Brand 100% In-Houseirlabs2023-02-09T12:37:44+00:00February 9, 2023|
adastrahold2023-01-27T21:33:56+00:00Adastra Holdings Reports Third Quarter Results; Demonstrating Third Consecutive Quarter of Record Revenueadastrahold2023-01-27T21:33:56+00:00December 1, 2022|
